ScPharmaceuticals Analyst Ratings
ScPharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 185.71% | Craig-Hallum | → $20 | Initiates Coverage On | → Buy |
| 08/11/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 08/02/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 07/19/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 06/08/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/11/2023 | 185.71% | Maxim Group | $13 → $20 | Maintains | Buy |
| 05/11/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 03/23/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 01/27/2023 | 85.71% | SVB Leerink | $12 → $13 | Maintains | Outperform |
| 12/01/2022 | 257.14% | Cowen & Co. | → $25 | Initiates Coverage On | → Outperform |
| 11/10/2022 | 157.14% | HC Wainwright & Co. | $15 → $18 | Maintains | Buy |
| 11/10/2022 | 71.43% | SVB Leerink | $11 → $12 | Maintains | Outperform |
| 10/21/2022 | 100% | Jefferies | → $14 | Assumes | → Buy |
| 10/11/2022 | 57.14% | SVB Leerink | $6 → $11 | Upgrades | Market Perform → Outperform |
| 08/02/2022 | — | Maxim Group | Initiates Coverage On | → Buy | |
| 05/17/2022 | -14.29% | SVB Leerink | $5 → $6 | Maintains | Market Perform |
| 09/09/2021 | -14.29% | SVB Leerink | → $6 | Initiates Coverage On | → Market Perform |
| 11/30/2020 | 71.43% | SVB Leerink | $11 → $12 | Maintains | Market Perform |
| 05/27/2020 | 42.86% | SVB Leerink | $12 → $10 | Maintains | Market Perform |
| 05/13/2020 | 114.29% | HC Wainwright & Co. | $13 → $15 | Reiterates | → Buy |
| 10/15/2019 | 85.71% | HC Wainwright & Co. | → $13 | Initiates Coverage On | → Buy |
| 01/30/2019 | -28.57% | Leerink Swann | $12 → $5 | Downgrades | Outperform → Market Perform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/07/2023 | 185.71% | 克雷格-哈勒姆 | →$20 | 開始承保 | →購買 |
| 2023年08月11日 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 08/02/2023 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 07/19/2023 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 06/08/2023 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 2023年05月11日 | 185.71% | Maxim集團 | $13→$20 | 維護 | 買 |
| 2023年05月11日 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 購買→購買 |
| 03/23/2023 | 157.14% | HC Wainwright公司 | →$18 | 重申 | →購買 |
| 2023年1月27日 | 85.71% | SVB Leerink | $12→$13 | 維護 | 跑贏大盤 |
| 12/01/2022 | 257.14% | 考恩公司 | →$25 | 開始承保 | →跑贏大盤 |
| 2022年11月10日 | 157.14% | HC Wainwright公司 | $15→$18 | 維護 | 買 |
| 2022年11月10日 | 71.43% | SVB Leerink | $11→$12 | 維護 | 跑贏大盤 |
| 2022年10月21日 | 100% | 傑富瑞 | →$14 | 假設 | →購買 |
| 2022年10月11日 | 57.14% | SVB Leerink | $6→$11 | 升級 | 市場表現優於→ |
| 08/02/2022 | - | Maxim集團 | 開始承保 | →購買 | |
| 2022/05/17 | -14.29% | SVB Leerink | $5→$6 | 維護 | 市場表現 |
| 09/09/2021 | -14.29% | SVB Leerink | →$6 | 開始承保 | →市場表現 |
| 11/30/2020 | 71.43% | SVB Leerink | $11→$12 | 維護 | 市場表現 |
| 05/27/2020 | 42.86% | SVB Leerink | $12→$10 | 維護 | 市場表現 |
| 2020/05/13 | 114.29% | HC Wainwright公司 | $13→$15 | 重申 | →購買 |
| 2019年10月15日 | 85.71% | HC Wainwright公司 | →$13 | 開始承保 | →購買 |
| 2019年01月30日 | -28.57% | 利林克·斯旺 | $12→$5 | 評級下調 | 跑贏→市場表現 |
What is the target price for scPharmaceuticals (SCPH)?
ScPharmPharmticals(SCPH)的目標價是多少？
The latest price target for scPharmaceuticals (NASDAQ: SCPH) was reported by Craig-Hallum on September 7, 2023. The analyst firm set a price target for $20.00 expecting SCPH to rise to within 12 months (a possible 185.71% upside). 14 analyst firms have reported ratings in the last year.
克雷格-哈勒姆於2023年9月7日報道了SCPharmticals(納斯達克代碼：SCPH)的最新目標價。這家分析公司將目標價定為20美元，預計SCPH將在12個月內上漲(可能上漲185.71%)。過去一年，有14家分析公司公佈了評級。
What is the most recent analyst rating for scPharmaceuticals (SCPH)?
ScPharmticals(SCPH)的最新分析師評級是多少？
The latest analyst rating for scPharmaceuticals (NASDAQ: SCPH) was provided by Craig-Hallum, and scPharmaceuticals initiated their buy rating.
納斯達克(Sequoia Capital：SCPH)的最新分析師評級由克雷格-哈勒姆提供，SCPharmPharmticals啟動了買入評級。
When is the next analyst rating going to be posted or updated for scPharmaceuticals (SCPH)?
ScPharmticals(SCPH)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of scPharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for scPharmaceuticals was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與scPharmPharmticals的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。ScPharmticals的上一次評級是在2023年9月7日提交的，所以你應該預計下一次評級將在2024年9月7日左右的某個時候公佈。
Is the Analyst Rating scPharmaceuticals (SCPH) correct?
分析師對SCPharmPharmticals(SCPH)的評級正確嗎？
While ratings are subjective and will change, the latest scPharmaceuticals (SCPH) rating was a initiated with a price target of $0.00 to $20.00. The current price scPharmaceuticals (SCPH) is trading at is $7.00, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的scPharmPharmticals(SCPH)評級是以0.00美元至20.00美元的目標價啟動的。ScPharmticals(SCPH)目前的交易價格為7.00美元，在分析師的預測範圍內。